Alexandria Real Estate Equities Is Going to Transform With a 27.2% Future Pe Ratio

Core Fundamental Data

Alexandria Real Estate Equities (NYSE: ARE) is a specialized life science REIT with a highly concentrated portfolio of laboratory and office real estate. As of September 30, 2025, total shareholders’ equity amounted to $16,639 million. With approximately 170.3 million shares outstanding (common stock $1,703 thousand, par value $0.01), this translates into a book NAV of approximately $97.7 per share. By comparison, at year-end 2024 this stood at roughly $103.9 (equity of $17,889 million as of 12/31/2024). This indicates that NAV per share declined modestly during 2025.

Results

In Q3 2025, ARE reported a net loss of $234.9 million (-$1.38 per share), bringing the year-to-date loss to $356.1 million (-$2.09 per share). While these losses are large from an accounting perspective (largely driven by impairments), Funds From Operations (FFO)—the standard REIT performance metric—amounted to $377.8 million in Q3 ($2.22 per share) and $1,166.3 million YTD ($6.85 per share). FFO was lower than in the comparable periods of 2024, partly due to lower occupancy and fewer property sales. Operating income declined slightly: same-property cash NOI was down 3.1% YTD (Q3) versus last year. North American occupancy currently stands at 90.6% (versus 94.7% a year earlier), a six-year low driven by tenant move-outs and rising sector vacancy.

Cash Position

Cash and equivalents totaled $579 million as of September 30, 2025, slightly above $552 million at year-end 2024. With unsecured debt of approximately $13.6 billion (12.045 + 1.549) and limited subordinated debt, the capital structure remains relatively solid (net debt/equity ~0.8x). That said, the company is facing rising interest and refinancing pressure, as recently highlighted by S&P.

Shares Outstanding and Buybacks

Shares outstanding declined modestly from roughly 172.2 million at year-end 2024 to approximately 170.3 million at the end of Q3 2025 due to share repurchases. ARE launched a $500 million buyback program in late 2024; as of the end of October 2025, approximately $241.8 million remained available. No shares were repurchased in Q3 2025. There have been no recent equity issuances or primary capital raises.

Portfolio Developments

In 2025, ARE completed modest sales of non-core assets. As of October 27, 2025, completed dispositions totaled $508 million (annual rent $4.3 million), with negotiations ongoing for an additional ~$1.0 billion. In October 2025, ARE sold $167.4 million of properties across three locations, realizing a gain of $4.4 million. Major developments also include the delivery of new projects: in Q3 2025, approximately 122k RSF at the Torrey Pines megacampus in San Diego came online (89% leased), and a ~466,598 RSF lease with a global pharmaceutical tenant (San Diego) was executed. These “Megacampus” projects (Boston, SF Bay Area, San Diego, NYC, etc.) are expected to drive growth: ARE estimates that projects delivered in 2025–26 will add approximately $111 million of incremental NOI.

Dividend Policy

Through Q3 2025, ARE paid a quarterly dividend of $1.32 per share (annual $5.19 in 2024). Due to operating pressure, however, the Board sharply reduced the Q4 2025 dividend to $0.72 per share (a 45% cut versus Q3). The full-year 2025 dividend therefore totals $3.96. The dividend yield (~8–9% at prior levels) has thus fallen to roughly ~5.4% based on the early-December 2025 share price. The dividend cut is intended to save approximately $410 million per year and strengthen the balance sheet. ARE is expected to remain a net-paying REIT; future (lower) dividends will likely align more closely with adjusted FFO/AFFO.

Valuation Based on NAV

As a starting point, we take NAV per share of approximately $98, representing intrinsic value based on book equity divided by shares outstanding. Given ARE’s nature as a property investment company, NAV is a standard valuation anchor.

We apply several adjustments. The sector is experiencing declining rents and occupancy. ARE recorded further property impairments in Q3 2025 (e.g., $323.9 million in Q3 alone). A small portion of the portfolio consists of higher-risk investments (approximately $1.5 billion in venture investments), where valuation uncertainty is higher. Currency risk is minimal, as ARE’s activities are almost entirely USD-denominated. The current market discount (ARE trades around $54, or ~0.55× NAV) reflects these risks.

We apply a rough discount for:

• Revaluations: Given downward trends in rents and rising vacancy, we conservatively assume ~10% lower current property values versus book.
• Private holdings: Joint ventures and venture investments are valued cautiously.
• Currency risk: Negligible, given minimal non-US exposure.

After adjustments (e.g., -10% on NAV), intrinsic value remains well above the current share price. For example, a NAV estimate of $98 with a 20% margin of safety (see below) yields an intrinsic value around $78—still far above the current market price (~$54).

Pro-Forma Effects

There has been no recent large equity issuance that would dilute NAV. On the contrary, the share count declined slightly due to buybacks. Therefore, no pro-forma adjustment is required.

Alternative Valuation Approaches

As a cross-check, dividend-based and cash-flow-based models can be applied:

Dividend Discount Model (DDM)

With the new lower annual dividend of $3.96 (2025), assuming long-term growth of ~2% and a required return of ~8–9% given sector and interest-rate risk, the implied valuation falls in the $60–70 range. For example, with D = $3.96, g = 2%, r = 8%, intrinsic value ≈ $67. Higher required returns or lower growth assumptions reduce this value, reflecting increased uncertainty.

DCF on FFO/AFFO

A traditional free-cash-flow DCF is less suitable due to ARE’s heavy reinvestment in development. Instead, adjusted FFO can serve as a proxy (e.g., ~$2.39 per quarter in 2024, trending toward ~2.20 currently). Using a discount rate of ~8–9% and modest growth assumptions yields valuations in the several-tens-of-dollars per share range. These results are highly sensitive to assumptions and broadly overlap with DDM outcomes.

While both DDM and DCF suggest that ARE could still be worth more than the current price even after the dividend cut and higher discount rates, ARE has historically been valued primarily on NAV and P/FFO metrics. Given volatile market conditions, the NAV approach remains the most relevant, with DDM serving as a reasonableness check.

Risk Profile and Margin of Safety

Portfolio Risks

ARE is almost entirely focused on life science real estate (labs/offices in research clusters), resulting in high sector concentration (biotech/tech/medical research). Geographic diversification is reasonable across major US clusters (Boston, SF, San Diego, Seattle, NYC, Research Triangle, etc.). Approximately 53% of rent comes from investment-grade or publicly listed tenants among the top 20, providing some stability. However, significant in-house development and private projects (pipeline ~$4.7 billion) increase illiquidity and execution risk.

Liquidity and Exit Risk

Non-listed assets (JVs, development projects, venture investments) total several billion dollars and cannot easily be sold at NAV on short notice. ARE mitigates this by actively disposing of non-core assets ($1–2 billion per year), but realized prices remain market-dependent. The recent dividend cut underscores management’s conservative stance, prioritizing cash preservation and debt reduction.

Currency Risk

Limited, as operations are almost entirely US-based.

Cyclical Sensitivity

The life science real estate market may be materially cyclical following pandemic-driven expansion and subsequent demand normalization. S&P expects occupancy to decline further to ~88–90% in 2026, increasing uncertainty around future rental income.

Capital Structure

Net debt/equity (~0.78x) remains manageable, but S&P notes that leverage could rise toward ~6x debt/EBITDA due to declining NOI. The BBB+ rating carries a negative outlook. While debt maturities are long and historically attractively priced, leverage remains a key risk factor.

Given these risks, we apply a margin of safety to NAV. Under the StockWatch methodology, this typically ranges from 0–35%. ARE’s specialized portfolio and structural headwinds justify a relatively high risk assessment. We conservatively apply a ~20% margin of safety. This accounts for further NOI declines, additional impairments, or weaker-than-expected asset sales. In a very negative scenario, a 30% margin could be justified; in a very optimistic scenario, 10% would suffice.

Price Target

NAV-Based Target

With a book NAV of ~$98 and a 20% margin of safety, intrinsic value is approximately $78. In a bullish scenario (10% margin), this rises to ~$88; in a bearish scenario (30% margin), to ~$69.

DDM / DCF-Based Estimates

The DDM estimate (5.4% dividend yield, 8–9% required return, low growth) produces values around $60–70. A DCF based on expected AFFO yields broadly similar results (~$70–80), depending on assumptions. These methods align in magnitude but skew slightly lower due to reduced cash flows and dividends.

Overall, a valuation near the current market price (~$54) does not appear justified. NAV- and income-based estimates suggest 20–60% upside from current levels. At ~$78, upside potential is roughly +44%. Even under conservative assumptions, the implied “floor” remains well above the current price, indicating potential undervaluation relative to intrinsic measures.

Market Sentiment and Technical Analysis

Technical Indicators

ARE’s share price (~$54 in early 2026) has recently traded around key moving averages. The 50-day moving average is around ~$53, while the 200-day average is near $71. The price currently sits slightly above the short-term average, suggesting mild near-term positivity, but remains well below the long-term trend. RSI (14) is around 45, indicating neutral momentum. Trend indicators (MACD, ADX) are mixed, with no strong buy or sell signal in the very short term. Overall, technical sentiment is neutral to cautiously positive.

Market Sentiment and News

Sentiment around ARE has been mixed. Some analysts view the valuation decline as an opportunity (e.g., Evercore ISI upgraded to Outperform with a $104 price target). JMP Securities remains highly optimistic (Outperform, PT $130). Conversely, credit agencies and cautious analysts warn of further pressure: S&P revised the outlook to negative (BBB+) in late 2025 due to declining occupancy and weaker rent expectations. The 45% dividend cut reinforced management’s conservative outlook. While the biotech sector (XBI index) has shown some recovery, large lease renewals scheduled for 2026 (e.g., 1.2 million RSF in Boston/SF/SD) still represent execution risk. Overall sentiment is moderately negative: skepticism about near-term growth persists, though investors see an attractive yield and potential upside if conditions stabilize.

Conclusion

Based on the analysis above, ARE appears undervalued relative to intrinsic value. The NAV-based approach yields a significantly higher value than the current market price, even after applying substantial margins of safety. Alternative valuation methods (DDM, DCF) also point to potential value in at least the $60–80 range. The current price (~$54) reflects a historically high dividend yield, now reduced due to the dividend cut and accounting losses. Investors must remain aware of the risks: the life science real estate market remains challenging, with declining NOI, vacant newly delivered space, and rising financing costs.

Entry Considerations

At current levels, the stock may offer an opportunity for long-term investors comfortable with sector- and company-specific risks. A 20% margin of safety provides some buffer, though it remains smaller than the current market discount (~45%). A re-rating depends on ARE stabilizing occupancy and executing non-core asset sales smoothly. Lower interest rates and a recovery in biotech investment would further improve the outlook.

Potential catalysts for revaluation include: (a) stabilization or recovery in occupancy through new leases or asset repositioning, (b) improved biotech capital markets benefiting tenants, (c) completion of planned asset sales at favorable prices, and (d) reduced interest expense through deleveraging.

If these factors materialize, the share price could move closer to—or above—intrinsic value. For now, the deep discount to NAV suggests the market is pricing in these catalysts only cautiously.

Sources: Financial data and management commentary are drawn from the most recent quarterly filings and press releases of Alexandria Real Estate. Technical indicators and analyst commentary are based on public investment sites and news sources. All amounts in USD.